Pharmacy to notify patients about recall

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

INDIANAPOLIS – A pharmacy will notify its patients about a voluntary recall.

Nora Apothecary and Alternative Therapies will contact about 300 specialty patients that have prescriptions. The owner of the pharmacy said it voluntarily recalled all of its sterile drugs made on or before April 19. The company made this decision after a U.S. Food and Drug Administration inspection.

“In the 30 years we’ve been doing this, we’ve never had a complaint,” Charles Lindstrom said.

Lindstrom said the company has been making sterile compounds for many years. Lindstrom said patients affected by the recall will receive a letter telling them what they need to do. If a patient has a reaction they can contact their doctor, the FDA and/or Nora Apothecary and Therapies. The person can call the pharmacy at (317) 251-9547.

Lindstrom said the FDA visited the facility during early April. The agency made similar trips to other compounding sites after a deadly fungal meningitis outbreak. The investigation found the New England Compounding Center distributed tainted inject-able steroids. Lindstrom said there is a difference between that case and this one.

When the FDA visited, Lindstrom said, they made suggestions about techniques and new equipment that is available.

“The equipment has already been put in place. It’s already been certified. We’re waiting for our pharmacist to be certified other than the new equipment,” Lindstrom said.

Lindstrom said the pharmacy could begin making sterile drugs within 14 days, adding that pharmacists will get recertified.
“We don’t want anything to happen to our patients. So, we decided just to do a recall and start fresh all over again,” Lindstrom said.

The sterile drugs impacted by the recall are liquid prescriptions like injections and eye drops.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.